Overview

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus